Richard Becker, MD
Staff Affiliate - OtherCards
About
Research
Publications
2026
Antiplatelet Strategies and the Unfinished Story of Thrombosis Prophylaxis
Becker R. Antiplatelet Strategies and the Unfinished Story of Thrombosis Prophylaxis. Circulation Research 2026, 139: e328844. PMID: 42313906, DOI: 10.1161/circresaha.126.328844.Peer-Reviewed Original ResearchAdvancing cancer therapeutics: new perspectives on mechanisms, regulatory and policy challenges, and innovative multi-modality strategies for the early detection of cardiotoxicity
Becker R. Advancing cancer therapeutics: new perspectives on mechanisms, regulatory and policy challenges, and innovative multi-modality strategies for the early detection of cardiotoxicity. Journal Of Thrombosis And Thrombolysis 2026, 1-8. PMID: 42268506, DOI: 10.1007/s11239-026-03282-8.Peer-Reviewed Original ResearchFood and Drug AdministrationEarly detection of cardiotoxicityCancer therapeuticsAt-risk populationsDetection of cardiotoxicityUnited States Food and Drug AdministrationStates Food and Drug AdministrationEarly detectionPatient safetyTransform careGuideline developmentPatient careHealth agenciesStructured clinical trialsMulti-modal strategyClinical guidelinesTargeted agentsCardiovascular safetyCardiotoxicity riskPreclinical assessmentClinical trialsCardiac monitoringCardiovascular endpointsDrug AdministrationCardiotoxicityClinical spectrum and mechanistic insights into cardiotoxicity from cancer therapies
Becker R. Clinical spectrum and mechanistic insights into cardiotoxicity from cancer therapies. Journal Of Thrombosis And Thrombolysis 2026, 1-10. PMID: 42228348, DOI: 10.1007/s11239-026-03336-x.Peer-Reviewed Original ResearchDefinition of cardiotoxicityOvert heart failureSpectrum of presentationCancer treatment decisionsGuideline-directed therapyTherapeutic decision-makingPatient-reported outcomesOptimal patient careDose modificationTherapy discontinuationPatient safetyClinical spectrumMultidisciplinary managementClinical manifestationsHeart failurePatient careMyocardial injuryCardiotoxic effectsCardiovascular effectsCancer therapyCardiotoxicityTreatment decisionsIndirect cardiovascular effectsCancer therapeuticsIncidence patternsInnovative strategies for early detection of cardiotoxicity: artificial intelligence and multi-modality collaborative models
Becker R. Innovative strategies for early detection of cardiotoxicity: artificial intelligence and multi-modality collaborative models. Journal Of Thrombosis And Thrombolysis 2026, 1-11. PMID: 42213336, DOI: 10.1007/s11239-026-03262-y.Peer-Reviewed Original ResearchReal-world evidencePublic health policiesOncology carePatient safetyFood and Drug AdministrationHealth policyHealth systemEarly detectionTransparent data sharingGuidance developmentData elementsOncology centersCardio-OncologyCollaborative modelEarly detection of cardiotoxicityDetection of cardiotoxicityPatient groupPreparedness frameworkUnited States Food and Drug AdministrationData standardsStates Food and Drug AdministrationCross-centerWorld evidencePost-marketing phasePublic-private partnershipRegulatory challenges and current policy for cardiotoxicity detection in oncology drug development
Becker R. Regulatory challenges and current policy for cardiotoxicity detection in oncology drug development. Journal Of Thrombosis And Thrombolysis 2026, 1-15. PMID: 42213338, DOI: 10.1007/s11239-026-03337-w.Peer-Reviewed Original ResearchFood and Drug AdministrationEuropean Medicines AgencyPriority medicinesTime to therapyUnited States Food and Drug AdministrationStates Food and Drug AdministrationOncology drug developmentAntibody-drug conjugatesCardiac phenotypeCardiotoxicity detectionTargeted agentsAccelerated approvalDose safetyOncology therapeuticsCardiovascular riskSurrogate endpointsBreakthrough therapiesDrug AdministrationCardiotoxicityMedicines AgencyCardiotoxicity assessmentDrug approvalPost-marketingDrug developmentExpedited pathways250 Years of Medicine and Democracy in America
Becker R. 250 Years of Medicine and Democracy in America. The American Journal Of Medicine 2026 PMID: 42173465, DOI: 10.1016/j.amjmed.2026.05.011.Peer-Reviewed Original ResearchEthical governancePublic health systemEvolution of medicinePublic health infrastructurePublic health achievementsModern public health systemMedical ethicsPopulation health protectionHuman dignityYear of medicineHealth literacyHealth democracyIndividual well-beingHealth systemHistorical figuresActive practicePersistent disparitiesErosion of trustDemocratic processDemocratic societyDemocratic idealsHealth achievementsHealth infrastructureCivic valuesNation’s foundingRetraction: Mechanism(s) of factor XI inhibition in clinical practice
Becker R. Retraction: Mechanism(s) of factor XI inhibition in clinical practice. Blood Advances 2026, 10: 2538-2540. PMID: 41979876, PMCID: PMC13083641, DOI: 10.1182/bloodadvances.2025019213.Peer-Reviewed Original ResearchCorrection: Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management
Becker R. Correction: Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management. Journal Of Thrombosis And Thrombolysis 2026, 59: 526-530. PMID: 41622394, PMCID: PMC13018056, DOI: 10.1007/s11239-025-03234-8.Commentaries, Editorials and Letters
2025
Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction
Du W, Ringer M, Huang W, Desai D, Khandakar G, Esqueda L, Wang C, Guan J, Becker R, Sadayappan S, Fan G, Wang Y, Fan Y. Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction. Circulation 2025, 153: 653-672. PMID: 41410033, PMCID: PMC13085451, DOI: 10.1161/circulationaha.124.071774.Peer-Reviewed Original ResearchCardiac microvascular endothelial cellsDOX-induced cardiac dysfunctionMicrovascular endothelial cellsCardiac dysfunctionCardiac functionDoxorubicin treatmentEndothelial cellsProtective effectCardiotoxicity associated with doxorubicinTransgenic miceEC damageCardiotoxicity associated with chemotherapyMeasures of cardiac functionSecretion of proinflammatory cytokinesProinflammatory cytokine releaseTreated with doxorubicinEffective chemotherapeutic drugsIn vivoEC barrier integrityInhibitory effectMouse cardiac microvascular endothelial cellsEC in vitroPerivascular fibrosisEndothelial toxicityCardiovascular toxicityDiscernment and finding joy in medicine: Commentary
Becker R. Discernment and finding joy in medicine: Commentary. The American Journal Of Medicine 2025, 139: 393-394. PMID: 41177425, DOI: 10.1016/j.amjmed.2025.10.031.Commentaries, Editorials and Letters
Clinical Care
Overview
Richard Becker, MD, is a neuoradiologist specializing in radiology and biomedical imaging. He uses medical imaging techniques to diagnose and monitor a wide range of conditions, offering patients insights into their health using technologies such as X-ray, MRI, and CT scans.
At Yale School of Medicine, Dr. Becker is involved in radiology-related research, working on techniques to enhance diagnostic accuracy and patient outcomes.
He received his medical degree from New York Medical College.
Clinical Specialties
Radiology & Biomedical Imaging
Board Certifications
Diagnostic Radiology
- Certification Organization
- AB of Radiology
- Original Certification Date
- 1984
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.